MigraineMind research summary
Influence of CYP450 Polymorphisms on Analgesic Response to Continuous Ketamine Infusion in Patients with Refractory Migraine: An Exploratory Study.
J Clin Pharmacol | 2026
Observational studySummary
Continuous intravenous ketamine infusion is a new treatment for severe migraines. Some patients experience different responses to this therapy. This study looked at how genes affect ketamine's effectiveness. Specifically, it focused on two enzymes: CYP2B6 and CYP3A4/5. These enzymes help break down ketamine in the body. Researchers examined 52 patients who received ketamine for their migraines. They wanted to see if variations in these genes influenced pain relief and side effects. The study used various statistical methods to analyze headache pain over time. Results showed that genetic differences could affect how quickly and effectively patients respond to ketamine. Understanding these genetic factors may help doctors predict treatment outcomes better. This could lead to personalized migraine treatments. Overall, the research highlights the importance of genetics in pain management and migraine therapy. Clinical relevance: This study indicates that genetic differences may influence ketamine's effectiveness for migraine treatment, potentially guiding personalized pain management strategies.
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.
